Buscar
Conduit Pharmaceuticals Inc
CDTAñadir a la lista de seguimiento
0.138USD
-0.004-2.82%
Horarios del mercado 09/23, 09:38（ET）
91.08KCap. mercado
0.00P/E TTM
Acerca de Conduit Pharmaceuticals Inc Compañía
CDT Equity Inc., formerly Conduit Pharmaceuticals, Inc. is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Through advanced co-crystallization and solidform technologies developed at its Cambridge facility, it is engaged in improving drug properties and has helped in extending the patent life of certain drugs by up to 20 years. Its pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health. It applies proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. In addition, the Company has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention.
Perfil de Conduit Pharmaceuticals Inc
Símbolo de cotizaciónCDT
Nombre de la empresaCDT Equity Inc
Fecha de salida a bolsaFeb 03, 2022
Director ejecutivoRegan (Andrew)
Número de empleados6
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 03
Dirección4851 Tamiami Trail North
CiudadNAPLES
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal34103
Teléfono16464919132
Sitio Webhttps://www.cdtequity.com/
Símbolo de cotizaciónCDT
Fecha de salida a bolsaFeb 03, 2022
Director ejecutivoRegan (Andrew)
Ejecutivos de Conduit Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ulrik Olsen
Mr. Ulrik Olsen
Independent Director
Independent Director
23.36K
--
Mr. Ulrik Olsen
Mr. Ulrik Olsen
Independent Director
Independent Director
23.36K
--
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Chairman of the Board
Independent Chairman of the Board
7.82K
--
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Chairman of the Board
Independent Chairman of the Board
7.82K
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
240.00
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
240.00
--
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Independent Director
Independent Director
18.00
--
Mr. Simon Jeremy Fry
Mr. Simon Jeremy Fry
Independent Director
Independent Director
18.00
--
Dr. Freda Lewis-Hall, M.D.
Dr. Freda Lewis-Hall, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Andrew Regan
Dr. Andrew Regan
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ulrik Olsen
Mr. Ulrik Olsen
Independent Director
Independent Director
23.36K
--
Mr. Ulrik Olsen
Mr. Ulrik Olsen
Independent Director
Independent Director
23.36K
--
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Chairman of the Board
Independent Chairman of the Board
7.82K
--
Ms. Chele Chiavacci Farley
Ms. Chele Chiavacci Farley
Independent Chairman of the Board
Independent Chairman of the Board
7.82K
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
240.00
--
Mr. James (Jamie) Bligh
Mr. James (Jamie) Bligh
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
240.00
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Conduit Pharmaceuticals Inc?
Los cinco principales accionistas de Conduit Pharmaceuticals Inc son: Mr. Ulrik Olsen
¿Cuántas instituciones poseen acciones de Conduit Pharmaceuticals Inc (CDT)?
A fecha de 2026Q1, 71 instituciones poseen acciones de Conduit Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 4.64K, lo que representa el 0.10% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 2745.00.